Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Haemonetics Co. (NYSE:HAE) have received a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $101.22.

HAE has been the subject of a number of recent research reports. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective for the company. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Raymond James restated a “strong-buy” rating and set a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $95.00 to $68.00 in a report on Friday, February 7th. Finally, JMP Securities dropped their price objective on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th.

Haemonetics Trading Down 1.8 %

NYSE HAE opened at $63.03 on Monday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.17 billion, a P/E ratio of 24.81, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics has a 52-week low of $58.80 and a 52-week high of $97.97. The firm has a 50-day moving average price of $66.05 and a 200 day moving average price of $74.70.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts expect that Haemonetics will post 4.55 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Cerity Partners LLC increased its stake in Haemonetics by 31.1% in the third quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier’s stock valued at $712,000 after acquiring an additional 2,102 shares during the period. FMR LLC grew its stake in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 10,774 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Haemonetics by 30.1% during the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock worth $341,000 after buying an additional 982 shares during the period. Finally, Paloma Partners Management Co acquired a new stake in Haemonetics in the 3rd quarter valued at $623,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.